3,4-Methylenedioxyphentermine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-2-methylpropan-2-amine
Other names
3,4-Methylenedioxyphentermine;
3,4-Methylenedioxy-alpha,alpha-dimethyl-1-ethane
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C11H15NO2/c1-11(2,12)6-8-3-4-9-10(5-8)14-7-13-9/h3-5H,6-7,12H2,1-2H3 ☒N
    Key: OIZBHKBNZXRXSM-UHFFFAOYSA-N ☒N
  • InChI=1/C11H15NO2/c1-11(2,12)6-8-3-4-9-10(5-8)14-7-13-9/h3-5H,6-7,12H2,1-2H3
    Key: OIZBHKBNZXRXSM-UHFFFAOYAY
  • NC(C)(C)CC1=CC(OCO2)=C2C=C1
Properties
C11H15NO2
Molar mass 193.246 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

3,4-Methylenedioxyphentermine (MDPH) is a lesser-known psychedelic drug. MDPH was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the dosage range is listed as 160–240 mg, and the duration as 3–5 hours.[1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. MDPH entry in PiHKAL
  2. "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.